GT Biopharma Announces Strategic Board Changes to Propel Innovation in Cancer Treatment
GT Biopharma Inc. has made strategic changes to its Board of Directors, appointing Andrew Ritter and Hilary Kramer, in a move aimed at driving innovation and growth in the company’s immuno-oncology therapies.
2 minutes to read